CDK9-IN-27

• Description :

  CDK9-IN-27 (Compound 6a) is a CDK9 inhibitor (IC50s: 0.424 μM) . CDK9-IN-27 induces apoptosis and cell cycle arrest at S stage. CDK9-IN-27 has cytotoxic action against HepG2, HCT-116 and MCF-7 cell lines, with IC50s of 10.31-40.34 μM. CDK9-IN-27 can be used for cancer research[1].

• UNSPSC :

  12352005

• Target :

  CDK

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/cdk9-in-27.html

• Solubility :

  10 mM in DMSO

• Smiles :

  ClC(C=C1)=CC=C1C(C(C(OCC)=O)=C(N)N2CC3=NC4=CC=CC=C4N3)=C(C#N)C2=O

• Molecular Formula :

  C23H18ClN5O3

• Molecular Weight :

  447.87

• References & Citations :

  [1]Husseiny EM, et al. Aminopyridone-linked benzimidazoles: a fragment-based drug design for the development of CDK9 inhibitors. Future Med Chem. 2023 Aug 16.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported